Theriva Licenses SYN-020, Refocuses on Cancer Pipeline

Theriva Biologics ( (TOVX) ) has issued an update.

On February 18, 2026, Theriva Biologics entered into a license agreement granting Rasayana Therapeutics an exclusive worldwide right to develop and commercialize SYN-020, an oral recombinant intestinal alkaline phosphatase designed to address metabolic and inflammatory disorders linked to gastrointestinal dysfunction and aging. Theriva received a $300,000 upfront payment and is eligible for up to $38 million in development, regulatory and sales milestones, along with tiered low to mid single-digit royalties and a share of any sublicensing revenue, while Rasayana assumes all development and commercialization costs and obligations.

The out-licensing of SYN-020 allows Theriva to shift resources toward its lead pancreatic cancer program VCN-01 while retaining economic upside if Rasayana successfully advances the asset into and through planned Phase 2 trials. The deal underscores growing interest in gut-organ axis biology as Rasayana integrates SYN-020 into its pipeline targeting chronic inflammatory, cardiometabolic and neurodegenerative diseases, potentially broadening the therapeutic reach of the enzyme and offering future value to both patients and Theriva shareholders if milestones and sales materialize.

The most recent analyst rating on (TOVX) stock is a Hold with a $0.17 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.

Spark’s Take on TOVX Stock

According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.

The score is primarily constrained by weak financial performance (pre-revenue losses, material cash burn, and a shrinking equity base that raises financing/dilution risk). Technical signals are mixed-to-weak with negative MACD and price below key longer-term averages. Offsetting these risks, corporate events are constructive, highlighted by positive Phase 2b data and EMA support for a pivotal Phase 3 trial.

To see Spark’s full report on TOVX stock, click here.

More about Theriva Biologics

Theriva Biologics, Inc., listed on NYSE American as TOVX, is a diversified clinical-stage biopharmaceutical company developing therapeutics to treat cancer and related diseases in areas of high unmet need. Its pipeline includes the oncolytic adenovirus VCN-01, designed to break down tumor stroma and enhance anti-tumor immune responses, and SYN-004 (ribaxamase), aimed at protecting the gut microbiome during beta-lactam antibiotic use to reduce pathogenic overgrowth and acute graft-versus-host disease in transplant patients.

The company is building a platform for intravenous, intravitreal and antitumoral delivery of oncolytic viruses, seeking to improve the effectiveness of co-administered cancer therapies. By focusing on both oncology and microbiome-protective approaches, Theriva targets difficult-to-treat conditions where current treatment options are limited, positioning itself in niche, high-unmet-need segments of the oncology and gastrointestinal-related therapeutics market.

Average Trading Volume: 5,249,453

Technical Sentiment Signal: Strong Sell

Current Market Cap: $6.5M

For a thorough assessment of TOVX stock, go to TipRanks’ Stock Analysis page.